威尔药业(603351) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 349.73 million, representing a 6.03% increase compared to CNY 329.83 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 36.59 million, up 5.73% from CNY 34.60 million year-on-year[4]. - Total operating revenue for Q1 2025 reached ¥349,725,188.55, an increase of 6.4% compared to ¥329,832,361.62 in Q1 2024[17]. - Net profit for Q1 2025 was ¥35,766,178.54, representing a 6.7% increase from ¥33,516,432.21 in Q1 2024[18]. - Earnings per share for Q1 2025 were ¥0.27, compared to ¥0.26 in Q1 2024, indicating a slight improvement[18]. Cash Flow - The net cash flow from operating activities decreased by 24.93% to CNY 22.21 million, down from CNY 29.59 million in the previous year[4]. - In Q1 2025, the cash inflow from operating activities was CNY 268,677,131.12, a decrease of 1.18% compared to CNY 273,321,097.29 in Q1 2024[21]. - The net cash flow from operating activities in Q1 2025 was CNY 22,211,455.90, down 25.06% from CNY 29,588,625.58 in Q1 2024[21]. - The cash outflow for investing activities in Q1 2025 totaled CNY 50,525,198.83, significantly higher than CNY 14,949,433.43 in Q1 2024[22]. - The net cash flow from investing activities was -CNY 49,625,198.83 in Q1 2025, compared to -CNY 12,034,860.57 in Q1 2024, indicating increased investment expenditures[22]. - Cash inflow from financing activities in Q1 2025 was CNY 121,000,000.00, up 51.25% from CNY 80,000,000.00 in Q1 2024[22]. - The net cash flow from financing activities improved to CNY 23,604,271.83 in Q1 2025, compared to a negative CNY 28,831,323.60 in Q1 2024[22]. - The ending cash and cash equivalents balance as of Q1 2025 was CNY 243,388,554.83, an increase from CNY 146,935,955.31 in Q1 2024[22]. Assets and Liabilities - Total assets at the end of Q1 2025 reached CNY 2.42 billion, reflecting a 1.81% increase from CNY 2.38 billion at the end of the previous year[6]. - Total assets as of the end of the reporting period were ¥2,423,991,651.70, compared to ¥2,380,913,919.67 at the end of the previous period, an increase of 1.8%[14]. - Total liabilities amounted to ¥679,504,636.68, slightly up from ¥672,715,662.08, reflecting a 1.2% increase[14]. - Non-current assets totaled ¥1,688,996,630.37, an increase from ¥1,663,708,867.64, indicating a growth of 1.5%[14]. - The company reported a decrease in accounts payable to ¥91,037,461.15 from ¥98,757,278.22, a reduction of 7.3%[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,012, with no preferred shareholders[9]. - The top ten shareholders collectively hold 70.12% of the company's shares, with the largest shareholder, Wu Renrong, owning 13.68%[9]. Expenses - Total operating costs for Q1 2025 were ¥307,861,914.39, up from ¥290,059,404.32 in Q1 2024, reflecting a year-over-year increase of 6.3%[17]. - Research and development expenses increased to ¥18,198,856.61 in Q1 2025, up from ¥15,768,635.95 in Q1 2024, marking a growth of 15.4%[17]. - The cash outflow for employee compensation in Q1 2025 was CNY 55,445,080.19, an increase of 15.06% from CNY 48,087,072.98 in Q1 2024[21]. - The company reported a decrease in tax payments, with CNY 14,492,378.79 in Q1 2025 compared to CNY 19,139,293.68 in Q1 2024, reflecting a 24.06% reduction[21]. Other Financial Metrics - The weighted average return on equity was 2.13%, a slight decrease of 0.03 percentage points from 2.16% in the previous year[4]. - The company reported a significant increase in prepayments, which rose by 36.96% due to higher raw material prepayments[7]. - Other receivables decreased by 35.26%, primarily due to a reduction in export tax refunds[7]. - Long-term borrowings increased by 57.14%, attributed to new medium to long-term bank loans[7].